Japan's Eisai aims for 2030 U.S. release of new Alzheimer's drug
TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked to symptoms, aiming to release it in the U.S. by fiscal 2030, Nikkei has learned.
Small-scale clinical trials are underway to confirm the safety of the drug candidate, which targets tau proteins. Such drugs, though difficult to develop, are expected to be highly effective if successful.